Characterization of Non-Monotonic Relationships between Tumor Mutational Burden and Clinical Outcomes

被引:0
|
作者
Anaya, Jordan [1 ]
Kung, Julia [2 ]
Baras, Alexander S. [1 ,3 ,4 ]
机构
[1] Johns Hopkins Univ, Dept Pathol, Sch Med, CRB II 152,1550 Orleans St, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Biomed Informat & Data Sci, Sch Med, Baltimore, MD USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA
[4] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA
来源
CANCER RESEARCH COMMUNICATIONS | 2024年 / 4卷 / 07期
关键词
CTLA-4; BLOCKADE; LANDSCAPE; MODELS;
D O I
10.1158/2767-9764.CRC-24-0061
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Potential clinical biomarkers are often assessed with Cox regressions or their ability to differentiate two groups of patients based on a single cutoff. However, both of these approaches assume a monotonic relationship between the potential biomarker and survival. Tumor mutational burden (TMB) is currently being studied as a predictive biomarker for immunotherapy, and a single cutoff is often used to divide patients. In this study, we introduce a two-cutoff approach that allows splitting of patients when a non-monotonic relationship is present and explore the use of neural networks to model more complex relationships of TMB to outcome data. Using real-world data, we find that while in most cases the true relationship between TMB and survival appears monotonic, that is not always the case and researchers should be made aware of this possibility.Significance: When a non-monotonic relationship to survival is present it is not possible to divide patients by a single value of a predictor. Neural networks allow for complex transformations and can be used to correctly split patients when a non-monotonic relationship is present.
引用
收藏
页码:1667 / 1676
页数:10
相关论文
共 50 条
  • [21] Effects of Tumor Mutational Burden and Gene Alterations Associated with Radiation Response on Outcomes of Postoperative Radiation Therapy in Non-Small Cell Lung Cancer
    Shaverdian, Narek
    Shepherd, Annemarie F.
    Li, Xingzhe
    Offin, Michael
    Lengel, Harry B.
    Gelblum, Daphna Y.
    Wu, Abraham J.
    Simone, Charles B. I. I. I. I.
    Rimner, Andreas
    Jones, David R.
    Chaft, Jamie E.
    Riaz, Nadeem
    Gomez, Daniel R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 113 (02): : 335 - 344
  • [22] Clinical metric of tumor mutational burden depicts colorectal cancer patients at the extremes
    Zheng, Ming
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [23] Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden
    van den Heuvel, Guus R. M.
    Kroeze, Leonie I.
    Ligtenberg, Marjolijn J. L.
    Grunberg, Katrien
    Jansen, Erik A. M.
    von Rhein, Daniel
    de Voer, Richarda M.
    van den Heuvel, Michel M.
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [24] Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcomes Based on Genomic Ancestry in Non-Small-Cell Lung Cancer
    Brawley, Otis W.
    Luhn, Patricia
    Reese-White, Deonna
    Ogbu, Uzor C.
    Madhavan, Sriraman
    Wilson, Gerren
    Cox, Meghan
    Ewing, Altovise
    Hammer, Christian
    Richie, Nicole
    JCO GLOBAL ONCOLOGY, 2021, 7 : 1537 - 1546
  • [25] Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden
    Cui, Yunlong
    Jiang, Ning
    HUMAN CELL, 2022, 35 (04) : 1192 - 1206
  • [26] Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients
    Parisi, Rose
    Patel, Roshal R.
    Rood, Gavrielle
    Bowden, Acacia
    Turco, George
    Korones, David N.
    Andolina, Jeffrey R.
    Comito, Melanie
    Barth, Matthew
    Weintraub, Lauren
    PEDIATRIC BLOOD & CANCER, 2023, 70 (03)
  • [27] Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer
    Park, Song Ee
    Park, Kyunghee
    Lee, Eunjin
    Kim, Ji-Yeon
    Ahn, Jin Seok
    Im, Young-Hyuck
    Lee, Choonghoon
    Jung, Hun
    Cho, Soo Youn
    Park, Woong-Yang
    Cristescu, Razvan
    Park, Yeon Hee
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [28] Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
    Hsiehchen, David
    Espinoza, Magdalena
    Valero, Cristina
    Ahn, Chul
    Morris, Luc G. T.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)
  • [29] Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
    Negrao, Marcelo, V
    Skoulidis, Ferdinandos
    Montesion, Meagan
    Schulze, Katja
    Bara, Ilze
    Shen, Vincent
    Xu, Hao
    Hu, Sylvia
    Sui, Dawen
    Elamin, Yasir Y.
    Le, Xiuning
    Goldberg, Michael E.
    Murugesan, Karthikeyan
    Wu, Chang-Jiun
    Zhang, Jianhua
    Barreto, David S.
    Robichaux, Jacqulyne P.
    Reuben, Alexandre
    Cascone, Tina
    Gay, Carl M.
    Mitchell, Kyle G.
    Hong, Lingzhi
    Rinsurongkawong, Waree
    Roth, Jack A.
    Swisher, Stephen G.
    Lee, Jack
    Tsao, Anne
    Papadimitrakopoulou, Vassiliki
    Gibbons, Don L.
    Glisson, Bonnie S.
    Singal, Gaurav
    Miller, Vincent A.
    Alexander, Brian
    Frampton, Garrett
    Albacker, Lee A.
    Shames, David
    Zhang, Jianjun
    Heymach, John, V
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
  • [30] Association between Tumor Mutational Burden, Stromal CD8+ Tumor-Infiltrating Lymphocytes, and Clinical Factors in Cervical Cancers Treated with Radiotherapy
    Ruan, Hanguang
    Oike, Takahiro
    Sato, Hiro
    Ando, Ken
    Ohno, Tatsuya
    CANCERS, 2023, 15 (04)